Current treatment of neuromuscular diseases

Archives of Neurology

Volumn 57, Issue 7, 2000, Pages 939-943

  Kokontis, Lisa ^a   Gutmann, Ludwig ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; PREDNISOLONE ACETATE; PREDNISONE; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; DRUG EFFICACY; DRUG INDUCED DISEASE; EATON LAMBERT SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; MYASTHENIA GRAVIS; NEUROMUSCULAR DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; REVIEW;

EID: 0033938775     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.7.939     Document Type: Review

References (30)

1. Mastalgia FL, Phillips BA, Zilko P. Treatment of inflammatory myopathies. Muscle Nerve. 1997;20:651-664.
2. Guillain Barré Syndrome Steroid Trial Group. Double blind trial of intravenous methylprednisolone in Guillain Barré syndrome. Lancet. 1993;341:586-590.
3. The Guillain Barré Syndrome Study Group. Plasmapheresis and acute Guillain Barré syndrome. Neurology. 1985;35:1096-110-4.
4. French Cooperative Group on Plasma Exchange in Guillain Barré Syndrome. Efficacy of plasma exchange in Guillain Barré syndrome: a role of replacement fluids. Ann Neurol. 1987;22:753-761.
5. Plasma Exchange/Sandglobulin Guillain Barré Syndrome Trial Group. A randomized trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain Barré syndrome. Lancet. 1997;349:225-230.
6. van der Meche FGA, van Doom PA. Guillain Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol. 1995;37(suppl 1):S14-S31.
7. Kleyweg RP, van der Meche FGA. Treatment fluctuations in Guillain Barré syndrome after high dose immunoglobulins or plasma exchange. J Neurol Neurosurg Psychiatry. 1991;54:957-960.
8. Barohn RJ, Kissel JT, Warmolts R, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course and recommendations for diagnostic criteria. Arch Neurol. 1989;46:878-884.
9. Dyck PJ, Litchy WJ, Kratz KM, et al. Plasma exchange vs. immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838-845.
10. Mahattanakul W, Crawford TO, Griffin JW, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin A. J Neurol Neurosurg Psychiatry. 1996;60:185-187.
11. Gorson KG, Ropper AH, Clark BD, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with Interferon alpha 2a. Neurology. 1998;50:84-87.
12. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 gangliosides. Ann Neurol. 1988;24:73-78.
13. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994;57:778-783.
14. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in pa-tients with motor neuron syndromes associated with anti-GM1 antibodies: a double blind placebo controlled study. Neurology. 1994;44:429-432.
15. Van den Berg LH, Kerkhoff H, Oey P, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulin: a double blind placebo controlled study. J Neural Neurosurg Psychiatry. 1995;59:248-252.
16. Azulay JP, Rihet P, Pouget J, et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry. 1997;62:391-394.
17. Nobile-Orazio E, Meucci N. Berberi S, et al. High dose intravenous immunoglobulin in multifocal motor neuropathy. Neurology. 1993;43:537-544.
18. Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996: 47(suppl 4):S233-S241.
19. Bensimon G, Lacomblez L, Meininger J, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585-591.
20. Elliot J, Snider W. Motor neuron growth factors. Neurology. 1996;47(suppl 2): S47-S53.
21. Miller R. Petajan J, Wilson B, et al. A placebo controlled trial of rhCNTF in amyotrophic lateral sclerosis. Ann Neurol. 1996;39:256-260.
22. Amyotrophic Lateral Sclerosis CNTF Treatment Study Group. Double blind placebo controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in ALS. Neurology. 1996;46:1244-1249.
23. Newsom-Davis J. Vincent A, Wilson SG. et al. Long term effects of repeated plasma exchange in myasthenia gravis. Lancet. 1979;1:464-468.
24. Lewis RA, Selwa JF, Lisak RP. Myasthenia gravis: immunological mechanisms and immunothera'py. Ann Neurol. 1995;37(suppl 1):S51-S62.
25. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 1997;41:789-796.
26. Pascuzzi RM, Coslett HB, Johns TR. Long term corticosteroid treatment in myasthenia gravis. Ann Neurol. 1984;15:291-298.
27. Tindall RS, Rollins JA, Phillips T, et al. Preliminary results of a double blind, randomized, placebo controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316:719-724.
28. Perez MC. Buot WL, Mercado-Danguilan C, et al. Stable remissions in myasthenia gravis. Neurology. 1981;31:32-37.
29. Jaretzki A, Penn AS, Younger DS, et al. "Maximal" thymectomy for myasthenia gravis. J Thorac Cardiovasc Surg. 1988;95:747-757.
30. Sanders DB. Lambert-Eaton myasthenic syndrome: clinical diagnosis, immunemediated mechanisms and update on therapies. Ann Neurol. 1995:37(suppl 1): S63-S73.